Cutaneous radiation injury occurs on a functional, cellular, and gross level. Radiation therapy is the major modality in the management of cancer treatment along with the surgery and chemotherapy. Most common side effect of the radiation is the acute skin reaction which usually range from mild to confluent moist desquamation.
This report contains market size and forecasts of Cutaneous Radiation Injury Drug in Global, including the following market information:
Global Cutaneous Radiation Injury Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cutaneous Radiation Injury Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cutaneous Radiation Injury Drug include Merck, Novartis, Johnson & Johnson, Pfizer, Amgen, Roche, Eli Lily, AstraZeneca and Teva. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cutaneous Radiation Injury Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cutaneous Radiation Injury Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cutaneous Radiation Injury Drug Market Segment Percentages, by Type, 2021 (%)
Oral Drug
Topical Drug
Global Cutaneous Radiation Injury Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cutaneous Radiation Injury Drug Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Online Pharnacies
Retail Pharmacies
Global Cutaneous Radiation Injury Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cutaneous Radiation Injury Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cutaneous Radiation Injury Drug revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cutaneous Radiation Injury Drug revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Johnson & Johnson
Pfizer
Amgen
Roche
Eli Lily
AstraZeneca
Teva